Skip to contentI
Inhibikase Therapeutics, Inc.
I
IKTInhibikase Therapeutics, Inc. Q3 2024 · 10-Q
Revenue$0.00$0.00−100.0% vs Q3 2023 Net Income-$5.78M-$5.78MN/M vs Q3 2023 EPS Diluted-$0.65-$0.65N/M vs Q3 2023 Operating Income-$5,827,476N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Inhibikase Therapeutics, Inc. · CIK 1750149 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$4,881,100N/M ended Sep 30, 2024 · filed Nov 14, 2024 · 45 d after period end